Aptose Biosciences (TSE:APS) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aptose Biosciences has announced that its new triplet therapy protocol for treating newly diagnosed AML patients has been approved by the FDA to proceed. Furthermore, an abstract on the therapy’s safety and efficacy has been submitted for presentation at an upcoming ASH annual meeting. The company also addressed a Nasdaq deficiency notice regarding its share price.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.